Repost from other board might be harder to read without the

New Post Public Reply Private Reply Replies (0) Message Board
F1ash
Repost from other board might be harder to read without the bold and colored text.

Some DD on Placebo effect during Psoriasis trials.


At week 26 and across both studies for subjects receiving placebo, the PASI 75 was 9% (48/506) and the PASI 50 (proportion of subjects who achieved at least 50% improvement from baseline) was 27% (135/506)

CONCLUSION:

While these large-scale, robust studies demonstrated that rosiglitazone is not active in psoriasis, they also showed that for a large proportion of subjects receiving placebo, the expectation of a successful treatment, the favorable adverse effect profile of the drug, and the supportive environment of a clinical study conferred beneficial effects. These results may have implications for the design of future placebo-controlled studies in patients with psoriasis.

http://www.ncbi.nlm.nih.gov/pubmed/17428114

TRIAL DESIGN

THREE OF THE FOUR ARMS ARE PRURISOL

Active Comparator: 50mg of Purisol daily
One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days
Drug: Prurisol
50mg tablet
Other Name: Purisol, 50mg tablet
Active Comparator: 100mg of Purisol daily
One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days
Drug: Prurisol
50mg tablet
Other Name: Purisol, 50mg tablet
Active Comparator: 200mg of Purisol daily
Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days
Drug: Prurisol
50mg tablet
Other Name: Purisol, 50mg tablet
Placebo Comparator: Placebo daily
Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days
Drug: Placebo
Sugar pill designed to match Purisol tablet
Other Name: Matching Placebo to Purisol tablet



Status


News
Enrollment Approximately 50 Percent Complete in Cellceutix Phase 2 Clinical Trial of Prurisol for Chronic Plaque Psoriasis

BEVERLY, MA–(Marketwired – Sept 30, 2015) – Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, today announces that the Company’s Phase 2 clinical trial of the oral drug candidate Prurisol for psoriasis has now enrolled approximately 50 percent of the planned number of patients. The trial was designed to enroll 100 patients with active mild to moderate chronic plaque psoriasis.

http://cellceutix.com/enrollment-approximatel...7bTUE.dpbs


What we should/could expect from the clinical responses. Based on the Lab summary.

Prurisol (10 mg/kg PO twice/ day x 21 days)

» 84% reduction in lesion appearance

» 99% reduction in lesions based on histology

» 96% reduction in serum PRINS

» 87% reduction in serum IL-20

» No reoccurrence of lesions within 180 days
- See more at: http://cellceutix.com/prurisol/#sthash.pgq6pZrb.dpuf




Summary:

A minimum of 50 Patients have completed the entire 84 days to end of treatment.

5 should have 75% clearance (9%)
15 should have 50% clearance (27%)

3 of the 4 arms are Prurisol
If Prurisol is ineffective ~30 of the 50 should show less than 50% clearance. Really none (or very very few) should have greater than 75% clearance.

If they are seeing "complete responses" or if more than the numbers referenced above are showing high percentage clearance than they will have some pretty good clues that Prurisol is a winner. Might not be to hard to get, say 50 million in up front payment for a ~500 million dollar a year orally available psoriasis treatment with predictable side effects.



A good visual PASI reference.

http://www.dermnetnz.org/scaly/pasi.html

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 104

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 81

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading

Top 5 Most Recently Viewed Articles

Larry Chen's Transformative Journey in Automotive Photography

Updated Category News Views 460

Celebrating 20 Years of Automotive Photography Renowned automotive photographer Larry Chen presents his first-ever book titled Life at Shutter Speed: Two Decades of Larry Chen Photography. This extensive 400-page work features exceptional highlights from Chen's impressive career, along with captivating never-before-seen images. What’s Inside the Book? Life at Shutter...

Continue Reading
Kemper Corporation Achieves Record Stock High of $71.71

Updated Category News Views 157

Kemper Corporation Achieves New Stock Milestone Kemper Corporation (NYSE: KMPR) has reached an impressive milestone by achieving a remarkable 52-week high of $71.71. This achievement not only signifies a substantial uptrend for the diversified insurance holding but also reflects a commendable 67.95% increase in its stock value over the past year. The rising confidence...

Continue Reading
Rising Online Vaping Markets: A Challenge for Local Stores

Updated Category News Views 114

Challenges Faced by Local Convenience Stores in Quebec Local convenience stores in Quebec are confronting significant challenges due to the rise of online vaping sales. As these businesses grapple with a ban on flavored vapor products, introduced by Health Minister Christian Dubé, they are witnessing a shift in consumer behavior. This change has driven many customers to...

Continue Reading
Krispy Kreme Shareholders Invited to Join Class Action Lawsuit

Updated Category News Views 485

Krispy Kreme Investors: The Class Action Lawsuit Explained Krispy Kreme, Inc. (NASDAQ: DNUT) is facing a class action lawsuit that is generating significant attention among investors. This suit has been initiated by Robbins LLP following concerns about misleading statements made by the company's executives regarding its partnership with McDonald's. For anyone invested in...

Continue Reading
DexCom, Inc. Class Action Notice: Your Chance to Join Efforts

Updated Category News Views 62

Important Warning for DexCom, Inc. Shareholders Investors holding shares of DexCom, Inc. (NASDAQ: DXCM) should be aware of a critical opportunity to engage in a class action lawsuit. This notice emphasizes the essential details for shareholders who purchased shares during the specified class period. Your Participation Matters Shareholders are urged to reach out promptly...

Continue Reading